InfuSystem (NYSE:INFU) CEO Buys $17,660.00 in Stock

Key Points

  • InfuSystem director Paul Andrew Gendron bought 5,000 shares on May 8 at $8.88 apiece, spending $44,400 and increasing his holdings by 7.69% to 70,000 shares.
  • Analysts remain upbeat on INFU, with Roth Mkm reaffirming a buy rating and raising its price target to $15.00; the stock has a consensus rating of “Moderate Buy.”
  • Institutional investors own most of the stock, with 71.13% held by institutions, while shares recently traded at $8.41, below both the 50-day and 200-day moving averages.

InfuSystem Holdings, Inc. (NYSE:INFU - Get Free Report) CEO Carrie Lachance acquired 2,000 shares of the stock in a transaction on Friday, May 8th. The shares were acquired at an average price of $8.83 per share, with a total value of $17,660.00. Following the transaction, the chief executive officer directly owned 237,123 shares of the company's stock, valued at $2,093,796.09. The trade was a 0.85% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Carrie Lachance also recently made the following trade(s):

  • On Monday, May 11th, Carrie Lachance bought 1,000 shares of InfuSystem stock. The stock was purchased at an average price of $8.46 per share, with a total value of $8,460.00.

InfuSystem Price Performance

InfuSystem stock opened at $8.41 on Wednesday. The firm has a 50-day moving average price of $9.67 and a 200-day moving average price of $9.20. The firm has a market capitalization of $169.83 million, a PE ratio of 140.19 and a beta of 1.49. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50. InfuSystem Holdings, Inc. has a 12-month low of $5.08 and a 12-month high of $11.04.

Analyst Ratings Changes




Separately, Roth Mkm reissued a "buy" rating and issued a $15.00 price objective (up from $14.00) on shares of InfuSystem in a research report on Tuesday, February 24th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $15.00.

Check Out Our Latest Stock Report on INFU

Hedge Funds Weigh In On InfuSystem

A number of institutional investors have recently modified their holdings of INFU. Cubist Systematic Strategies LLC purchased a new position in shares of InfuSystem during the first quarter worth approximately $129,000. Jane Street Group LLC purchased a new position in shares of InfuSystem during the first quarter worth approximately $96,000. Acadian Asset Management LLC increased its position in shares of InfuSystem by 219.1% during the first quarter. Acadian Asset Management LLC now owns 39,117 shares of the company's stock worth $208,000 after acquiring an additional 26,860 shares during the period. American Century Companies Inc. increased its position in InfuSystem by 147.4% during the 2nd quarter. American Century Companies Inc. now owns 117,812 shares of the company's stock valued at $735,000 after purchasing an additional 70,188 shares during the period. Finally, XTX Topco Ltd purchased a new position in InfuSystem during the 2nd quarter valued at about $185,000. 71.13% of the stock is owned by hedge funds and other institutional investors.

About InfuSystem

(Get Free Report)

InfuSystem Holdings Inc is a medical technology company that specializes in the rental, management and servicing of infusion pumps and associated devices used primarily for outpatient infusion therapy. The company provides a comprehensive suite of services that includes equipment delivery, setup and retrieval, preventive and corrective maintenance, reprocessing and quality assurance. InfuSystem's offerings are designed to help hospitals, ambulatory surgery centers, oncology clinics and private infusion suites streamline clinical operations and maintain compliance with safety standards.

In addition to pump rental and repair services, InfuSystem has expanded into remote patient monitoring solutions.

Further Reading

Insider Buying and Selling by Quarter for InfuSystem (NYSE:INFU)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at InfuSystem?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for InfuSystem and related companies.
From Our Partners
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles